[STUDYING SOME PHARMACOLOGICAL EFFECTS OF NEW 3-HYDROXYPYRIDINE DERIVATIVE]

Area of Science:

• Pharmacology
• Neuroscience
• Biochemistry

Background:

• 3-hydroxypyridine (3-HP) derivatives are explored for their potential therapeutic benefits.
• Existing actoprotective, nootropic, and neuroprotective agents often require high doses or have limitations.

Purpose of the Study:

• To evaluate the efficacy of a new 3-HP derivative, 2-ethyl-6-methyl-3-hydroxypyridine L-aspartate (3-HPA), as an actoprotector, antiamnesic, and neuroprotective agent.
• To compare the effects of 3-HPA with established drugs in various animal models.

Main Methods:

• Assessment of physical performance in rats using treadmill and swimming tests.
• Evaluation of antiamnesic effects in mice across different amnesia models.
• Investigation of neuroprotective effects in rats with induced brain ischemia.
• Comparative analysis with reference drugs like metaprot, ladasten, mexidol, and piracetam.

Main Results:

• Low doses of 3-HPA (1-5 mg/kg) significantly improved physical performance in rats, outperforming higher doses of metaprot and ladasten.
• Tryptophan, a gluconeogenesis inhibitor, blocked the physical performance enhancement induced by 3-HPA.
• 3-HPA demonstrated marked antiamnesic effects in mice, comparable or superior to mexidol and piracetam at specific doses.
• 3-HPA (30 mg/kg/day) provided significant neuroprotection against brain ischemia in rats, reducing neurological deficits more effectively than mexidol.

Conclusions:

• 2-ethyl-6-methyl-3-hydroxypyridine L-aspartate (3-HPA) is a potent actoprotective agent effective at low doses.
• 3-HPA exhibits significant antiamnesic and neuroprotective properties, suggesting broad therapeutic potential.
• The mechanism of action may involve pathways related to gluconeogenesis, and 3-HPA shows promise as an alternative to existing treatments.